<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959749</url>
  </required_header>
  <id_info>
    <org_study_id>QingdaoCH20161101</org_study_id>
    <nct_id>NCT02959749</nct_id>
  </id_info>
  <brief_title>Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic
      change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in
      non-small cell lung cancer. After a 10 to 14 months median progression-free survival with the
      treatment of first generation EGFR TKI, half of patients will get disease progression.For
      patients progression after treated with first line EGFR TKI and second line double bullets
      chemotherapy or chemotherapy then EGFR TKI, optimal third line therapy is quite critical
      important for benefit patients' survival. We conducted this study was aimed to compare the
      efficacy and toxicity between osimertinib and docetaxel-bevacizumab as the third line therapy
      in patients with local advanced or metastatic non-squamous cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>Average 10 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Progression Free Survival</condition>
  <arm_group>
    <arm_group_label>Docetaxel, bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGFR TKI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>80 mg oral daily; until disease progression, intolerable toxicities, or patient death.</description>
    <arm_group_label>EGFR TKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, bevacizumab</intervention_name>
    <description>Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.</description>
    <arm_group_label>Docetaxel, bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  local advanced or metastatic non-small cell lung cancer

          -  large cell lung carcinoma or adenocinoma

          -  Previously treated by TKI-Chemotherapy or Chemotherapy-TKI

          -  EGFR T790M positive

          -  No uncontrolled hypertension

          -  No active bleeding or thrombosis in recent 6 months

          -  No previously treated with VEGF antibody

        Exclusion Criteria:

          -  newly diagnosed thrombosis

          -  anti-coagulation therapy

          -  uncontrolled hypertension

          -  uncontrolled nephropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Qingdao Central Hospital, Qingdao Cancer Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao Central Hospital</investigator_affiliation>
    <investigator_full_name>Youxin Ji</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Osimertinib</keyword>
  <keyword>EGFR T790M Resistant Mutation</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Non Small Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

